In fact, intensive efforts have been made to treat inflammatory diseases through TNF neutralization, and multiple TNF-blocking agents, such as adalimumab, certolizuman pegol, etanercept, golimumab, and infliximan, are now approved for diseases such as juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, spondylarthritis, inflammatory bowel disease, and uveitis47,48. This evidence concerns the gene TNF and juvenile idiopathic arthritis.